Details of the Drug
General Information of Drug (ID: DMCLXO0)
Drug Name |
CENTAUREIDIN
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Centaureidin; Desmethoxycentaureidine; 17313-52-9; 5,7,3'-Trihydroxy-3,6,4'-trimethoxyflavone; NSC-106969; UNII-548R7290J9; CHEMBL77552; MLS002701956; CHEBI:69356; 548R7290J9; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-3,6-dimethoxy-4H-chromen-4-one; centaureidine; NSC106969; NSC 106969; AC1NSTGP; SCHEMBL9953; cid_5315773; DTXSID50169530; MolPort-023-274-268; ZINC3871987; ZINC03871987; LMPK12113000; BDBM50064891; quercetagetin 3,6,4'-trimethyl ether; AKOS027326559; MCULE-7507998415; SMR001565538; 6-hydroxyquercetin 3,6,4''-trimethyl
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 360.3 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.8 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 3 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 8 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||